About us
Services & Solutions
Chemistry DMPK Discovery Biology Oncology Pharmacology Biologics
Medicinal Chemistry Computational Chemistry Synthetic Chemistry Analytical Chemistry Scale Up Chemistry
In Vivo PK and TK In Vitro ADME Bioanalytical Service Exploratory Toxicity In Rodents, Dogs and Monkeys Large Molecules Capabilities Bioanalytical Instruments
Biochemical Assays Cellular Assays Protein Science Assay Technologies Biophysics SPR Safety Pharmacology Screening Services Key Instruments
PDX CDX Orthotopic Models Syngeneic Models Humanized Mouse Models CAR-T and CAR-NK Mouse Models In Vitro Assays
Immunology Inflammation Metabolic NASH Respiratory Neuroscience
Systematic Antibody Discovery Service
Process R&D Scale Up Synthesis DS Manufacturing
Flow Chemistry Sugar Chemistry Peptide Chemistry Preparative Purification Capacity Process Safety Assessment
Synthetic and Scale Up Chemistry Parallel Synthesis
Flow Chemistry Kilo and Pilot Scale Production RSM and Intermediates Manufacturing QA EHS
Pre-Formulation Formulation, Analytical and Process Development Drug Product Manufacturing
Bioavailability Enhancement Modified Release
Commercial Manufacturing
Platforms
News & Resources
Careers
Contact us
CN EN
×
news
Company News Events Insights Webinars Virtual Tours
Congratulations to TaiGen for Anti-Influenza Drug TG-1000 Approved for Clinical Trial
Shanghai, June 4, 2020 – Congratulations to Fochon Pharmaceuticals (Fosun Pharma subsidiary) for their selective BCL-2 inhibitor FCN-338 and tablet (CXHL2000200, CXHL2000201, CXHL2000202) have been accepted by the CDE (Center
June 04, 2020
Congratulations to Fosun Pharma for Selective BCL-2 Inhibitor FCN-338 Accepted for Clinical Trial
Shanghai, May 28, 2020 – Congratulations to Fochon Pharmaceuticals (Fosun Pharma subsidiary) for their selective BCL-2 inhibitor FCN-338 and tablet (CXHL2000200, CXHL2000201, CXHL2000202) have been accepted by the CDE (Center
May 28, 2020
New Preclinical Models for NASH Provide Strong Clinical Relevance and Shortened Timelines
SAN DIEGO, May 26, 2020 – BioDuro, LLC, a leading drug discovery and development services organization, announced today the availability of two new preclinical models for Non-alcoholicsteatohepatitis
May 26, 2020
BioDuro & Silexon Form Strategic Collaboration to Develop New Anti-Cancer Drugs
SAN DIEGO, May 26, 2020 – BioDuro, LLC, a leading drug discovery and development services organization, announced today the availability of two new preclinical models for Non-alcoholicsteatohepatitis
May 26, 2020
BioDuro & neoX Partner to Create Next Generation Antibody Discovery Platform
SAN DIEGO and BEIJING, April 28, 2020 – BioDuro, LLC, a leading drug discovery and development services organization, and neoX, a leading-edge artificial intelligence and biophysics focused biotech, ann
April 28, 2020
Total 84 12...6789101112...1617
Subscribe to BioDuro-Sundia
Receive our newsletter and information on upcoming events
Your trusted partner from drug discovery and
development to commercialization

Home

About us

Services & Solutions

Platforms

News & Resources

Careers

Contact us

Explore

Discovery

Drug Substance

Drug Product

© 2023 BioDuro-Sundia. All rights reserved
Terms of Use Privacy Policy
We use necessary cookies to ensure our website functions properly and to keep it secure. These necessary cookies must be enabled. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can personalize or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third parties intervening on our website, please consult the Privacy Notice available in the site footer.
Accept all